


## Research

### Evolocumab and Coronary Disease in Statin-Treated Patients 2373

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental lowering of low-density lipoprotein cholesterol in statin-treated patients. In a randomized placebo-controlled clinical trial that enrolled 968 patients with angiographic coronary disease treated with statins, Nicholls and colleagues assessed the effect of PCSK9 inhibition with evolocumab—added to statin therapy—on progression of coronary atherosclerosis. The authors report that compared with statin therapy alone, evolocumab combined with statin therapy resulted in a greater decrease in percent atheroma volume.

**CME** [jamanetworkcme.com](http://jamanetworkcme.com)

### County-Level Trends in Mortality for Major Causes of Death 2385



In analyses of US vital statistics data representing more than 80 million deaths from 1980 through 2014, Dwyer-Lindgren and colleagues assessed county-level patterns in mortality rates for 21 major causes of death. The authors found large between-county disparities for all 21 causes of death. Geographic regions with elevated mortality rates differed among causes. For most causes of

death, both increases and decreases in county-level mortality rates were observed from 1980 through 2014. In an Editorial, Clark and Williams discuss the limitations and potential contributions of small area modeling approaches to inform priorities and design strategies to address geographic health disparities.

**Editorial** 2363

**Author Video Interview** [jama.com](http://jama.com) **CME** [jamanetworkcme.com](http://jamanetworkcme.com)

### Deep Learning Technology to Detect Diabetic Retinopathy 2402

Deep learning is a machine learning technique that allows an algorithm to program itself by learning predictive features from a set of demonstrative examples. Gulshan and colleagues report the development and validation of a deep learning algorithm to detect diabetic retinopathy and macular edema in retinal photographs. The authors compared performance of the deep learning algorithm with ophthalmologists' manual grading of retinal images ( $n = 128\,175$  and  $n = 11\,711$  in the algorithm development and validation sets, respectively). The authors report that the deep learning algorithm had high sensitivity and specificity for detecting diabetic retinopathy and macular edema. Two Editorials discuss the promise and challenges of applying deep learning technology in clinical care.

**Editorial** 2366 and 2368



## Humanities

### The Arts and Medicine

2340 New Frontiers of Medical Illustration  
K Bucher

### Poetry and Medicine

2434 Risk  
D Pucciani

### JAMA Revisited

2435 From Internal Combustion  
to Electricity

## Opinion

### Viewpoint

2353 Adapting to Artificial Intelligence: Radiologists and Pathologists as Information Specialists  
S Jha and EJ Topol

2355 Lesbian, Gay, and Bisexual Adolescents: Population Estimate and Prevalence of Health Behaviors  
S Zaza, L Kann, and LC Barrios

2357 Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy  
AS Kesselheim and J Avorn

2359 Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring Committees  
RJ Lewis, KA Calis, and DL DeMets

### A Piece of My Mind

2361 Coauthors  
BJ Oldfield and PR Duval

### Editorial

2363 Understanding County-Level, Cause-Specific Mortality: The Great Value—and Limitations—of Small Area Data  
CR Clark and DR Williams

2366 Artificial Intelligence With Deep Learning Technology Looks Into Diabetic Retinopathy Screening  
TY Wong and NM Bressler

2368 Translating Artificial Intelligence Into Clinical Care  
AL Beam and IS Kohane

2370 Two vs Three Doses of Human Papillomavirus Vaccine: New Policy for the Second Decade of the Vaccination Program  
LE Markowitz, E Meites, and ER Unger

### Instructions for Authors

[jama.com/public/instructionsforauthors.aspx](http://jama.com/public/instructionsforauthors.aspx)

Editor in Chief  
Howard Bauchner, MD

133 YEARS  
OF CONTINUOUS  
PUBLICATION

## Research (continued)

### Immunogenicity of 9-Valent HPV Vaccine: 2- vs 3-Dose Regimen 2411

Reduced dose schedules for the human papillomavirus (HPV) vaccine may improve vaccination coverage. In an international, open-label, noninferiority clinical trial involving 1518 participants, Iversen and colleagues evaluated the immunogenicity of a 2-dose regimen of a 9-valent HPV vaccine administered to boys and girls aged 9 to 14 years. The authors report that immunogenicity assessed 4 weeks after the last vaccine dose among girls and boys aged 9 to 14 years who received 2 doses of the 9-valent HPV vaccine—either 6 or 12 months apart—was noninferior to a 3-dose regimen given over 6 months in a comparison cohort of adolescent girls and young women aged 16 to 26 years. An Editorial by Markowitz and colleagues discusses HPV vaccine dose schedules.

Editorial 2370

## Clinical Review & Education

### Repeat *Clostridium difficile* Testing 2422

This JAMA Diagnostic Test Interpretation article presents a patient who had abdominal pain and frequent watery diarrhea after completing a course of azithromycin. A stool polymerase chain reaction test for the toxin B gene was positive—consistent with *Clostridium difficile* infection—and the patient's symptoms resolved after a 10-day course of oral metronidazole. Six weeks later, he presented with abdominal discomfort for 3 weeks relieved by bowel movements of typical consistency but increased frequency. A repeat stool *C difficile* toxin test was positive. How would you interpret this result?

### From The Medical Letter: Cannabis and Cannabinoids 2424

This *Medical Letter on Drugs and Therapeutics* article summarizes information about medical use of cannabis and cannabinoid products. Although a number of states permit some medical use of botanical marijuana (*Cannabis sativa*), cannabis is not approved as a treatment for any medical condition. Two oral prescription cannabinoids, dronabinol and nabilone, are approved for treatment of chemotherapy-associated nausea and vomiting not responsive to other antiemetics. Some evidence suggests that cannabinoid products may be effective for cancer-associated and neuropathic pain and for multiple sclerosis-associated spasticity.



## JAMA Patient Page

2440 Recovery After Stroke

## NEWS & ANALYSIS

### Medical News & Perspectives

2343 As Opioid Epidemic Rages, Complementary Health Approaches to Pain Gain Traction

### The JAMA Forum

2345 Genetically Modified Food Labeling: A "Right to Know"?

### JAMA Infographic

2347 Firearm Deaths in the United States and Globally, 1990-2015

2348 Capitol Health Call Research Across Borders

Fixing Obamacare Takes Back Seat, Poll Finds

Congress Delivers Medical Twofer

If at First You Don't Succeed

2349 News From the CDC Insurer Curbs Opioid Prescriptions

Health Workers' Risks for Respiratory Virus

## LETTERS

### Research Letter

2427 Trend in Ventilator-Associated Pneumonia Rates Between 2005 and 2013  
ML Metersky and Coauthors

### Comment & Response

2429 Lack of Benefit for Liraglutide in Heart Failure

2430 Factors Influencing Prescription Drug Costs in the United States

2432 Expectations for Physicians Prescribing Marijuana

2433 Correction

## Departments

2329 Staff Listing

2426 CME Questions

2436 Classified Advertising

2438 Journal Advertiser Index

2439 Contact Information

## Online @ jama.com



### Editor's Audio Summary

Howard Bauchner, MD, summarizes and comments on this week's issue.

### Author Interview

VIDEO Interview with Christopher J. L. Murray, MD, DPhil, author of "US County-Level Trends in Mortality Rates for Major Causes of Death, 1980-2014"

### Relaunch of jamanetwork.com



We've redesigned our website to make it easier for you to stay current with the research, opinion, and educational content published in the 12 journals of The JAMA Network.